Catalyst Funds Management
ABOS icon

Catalyst Funds Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Catalyst Funds Management’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-45,600
Closed -$108K – 644
2026
Q1 		$108K Buy
45,600
+16,000
+54% +$40.8K 0.02% 486
2025
Q4 		$62.5K Hold
29,600
– – 0.01% 322
2025
Q3 		$50.6K Buy
29,600
+9,900
+50% +$13.7K 0.01% 477
2025
Q2 		$22.9K Buy
+19,700
New +$21.2K 0.01% 421

Other funds holding ABOS

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Sands Capital Ventures
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ADAR1 Capital Management
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Knollwood Investment Advisory
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Ikarian Capital
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Catalyst Funds Management's ABOS Position: Q2 2026 in Review

Catalyst Funds Management sold out of Acumen Pharmaceuticals (ABOS) in Q2 2026, closing a stake of 45,600 shares — an estimated $108K sold.

Catalyst Funds Management first reported a position in ABOS in Q2 2025 and held it in 4 quarters. The position peaked at $108K in Q1 2026. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Catalyst Funds Management reported no remaining Acumen Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Catalyst Funds Management sold 45,600 Acumen Pharmaceuticals shares in Q2 2026, an estimated $108K.
  • Catalyst Funds Management first reported a position in Acumen Pharmaceuticals in Q2 2025 and held it in 4 quarters.
  • Catalyst Funds Management's Acumen Pharmaceuticals position peaked at $108K in Q1 2026.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.